Clinical Trials

  • Principal Investigator:

    Jennifer M. Bain, MD, PhD
    A natural history study of hnRNP and other genetic neurodevelopmental disorders.
  • Principal Investigator:

    Richard P. Mayeux, MD, MSc
    The goal of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. We are looking for families and/or individuals (affected or unaffected) of any ethnic background with a family history of Alzheimer's disease and willing to participate.
  • Principal Investigator:

    Patrick J. Lao, PhD
    The purpose of this study is to determine how inflammation is related to changes in the brain that occur during the progression of Alzheimer's disease. If you are eligible for this study, we will ask you to complete 3-4 study visits over the course of about 5 months. Participation includes memory testing, a blood draw, MRI, PET scans, and a lumbar puncture (spinal tap). You will be compensated $750 plus travel costs. After 2 years, we will invite you to return for a follow-up.
  • Principal Investigator:

    Patrick J. Lao, PhD
    The purpose of this study is to determine how inflammation is related to changes in the brain that occur during the progression of Alzheimer's disease. If you are eligible for this study, we will ask you to complete 3-4 study visits over the course of about 5 months. Participation includes memory testing, a blood draw, MRI, PET scans, and a lumbar puncture (spinal tap). You will be compensated $750 plus travel costs. After 2 years, we will invite you to return for a follow-up.
  • Principal Investigator:

    Davangere P. Devanand, MD
    There is considerable evidence that viruses, particularly a virus called herpes simplex, are commonly present in the brains of people with memory problems and may cause or contribute to worsening memory. The widely available and generic anti-viral medication Valacyclovir is FDA approved to treat herpes simplex as it is highly effective against herpes virus infections. This experimental study will test whether Valacyclovir is also helpful in treating memory problems in patients who have tested positive for the herpes virus. You may be eligible to participate if you: Have been experiencing...
  • Principal Investigator:

    Adam M. Brickman, PhD
    The purpose of this study is to better understand how vascular health affects your thinking abilities. We hope that these findings will ultimately lead to treatments aimed to reduce cognitive impairment and dementia. We are actively recruiting adults between the ages of 65 and 90 who note some decline in memory or thinking over the past 3 years (may be minor and go unnoticed by others) and who are of African American, Hispanic/Latino, or European ancestry. You will be asked to return to the Columbia University Medical Center every 12 to 18 months for a total of 3 assessments. At each visit,...
  • Principal Investigator:

    Rebecca Straus Farber, MD
    We need your help today to gather information about the experience of patients with autoimmune diseases of the central nervous system (multiple sclerosis (MS), neuromyelitis optica (NMO), and antiMOG associated disease (MOGAD)) in regards to COVID-19 vaccines. Because individuals with MS, NMO, and MOGAD were not included in the COVID-19 vaccine trials, we want to learn more about the experience of individuals with these autoimmune diseases and the vaccine. Because many patients with central nervous system autoimmune disease also take medications that affect the immune system, we want to find...
  • Principal Investigator:

    James M. Noble, MD, MS
    Funded by a multi-year research grant from the National Institute on Aging, the DIAN ObservationalStudy enrolls family members who have parents with a mutated gene known to cause dominantly inherited Alzheimer's (DIAD). Through the study, researchers follow individuals and family members to see if insights gained could lead to better understanding of how the disease progresses in order to identify solutions to prevent DIAD or minimize its impact.
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    This is a multicenter, Phase 2/3 study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Adults 18 yrs old or greater at the time of signing the informed consent.
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    The purpose of this study is to determine whether different genes are related to the amount of immune cell activity that occurs in the brain in patients with Alzheimer's disease. Participation in this study involves memory testing, a blood draw, MRI, and two PET scans. The second PET scan will involve putting a catheter in your wrist to draw blood during the scan. You will be compensated $500. After one year, we will invite you back to repeat some tests.

Pages